CRL Charles River Laboratories International, Inc. Common Stock
NYSE · Life Sciences Tools & Services · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 5, 2026
$290,19
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$146,2052 haftanın en düşüğü
$303,3152 haftanın en yükseği
Piyasa Değeri (MRQ)
$13.85B
P/E (TTM)
-60.5
Hisse Başına Kâr (TTM)
$-4.80
Gelir (TTM)
$4.00B
rozetleriniz
52 Haftlık Aralık
$146–$303
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$305
P/E
-60.5
ROE
-7.7%
Net Kâr Marjı
-6.0%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
CRL Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$290.19
Piyasa Değeri (MRQ)
$13.85B
P/E (TTM)
-60.5
Hisse Başına Kâr (TTM)
$-4.80
Gelir (TTM)
$4.00B
ROE (TTM)
-7.7%
D/E Borç/Özsermaye (MRQ)
0.0
52 Haftlık Aralık
$146–$303
CRL Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Charles River Laboratories International, Inc. Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients.
Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration (FDA). The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs.
As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.
History
Charles River was founded in 1947 by Henry Foster, a young veterinarian who purchased one thousand rat cages from a Virginia farm and set up a one-person laboratory in Boston overlooking the Charles River. He supplied local researchers with laboratory animals.
In 1955, the company's headquarters were relocated to their current home in Wilmington, Massachusetts. The organization became an international entity in 1966 by opening a new animal production facility in France.
The first commercial, comprehensive genetic monitoring program was implemented by Charles River in 1981. Three years later, they were acquired by Bausch & Lomb. In 1988, the organization began creating transgenic mice and rats. In the 1990s, they began in vitro endotoxin testing. In the 1990s, Jim Foster bought Charles River back from Bausch & Lomb, and the company later went public on the New York Stock Exchange.
Charles River launched the Humane Care Imperative in 2002, designed to raise awareness and train employees on animal welfare's importance. The same year, they were named "Company of the Year" by The Boston Globe. The company introduced preconditioning services in 2005 to provide customers with study-ready animals.
In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland.
In April 2019, Charles River announced it would cease its San Diego operations, moving the breeding of rodents for testing compounds to Hollister, California.
In March 2023, the Born Free USA animal welfare organization protested against Charles River's plan to export 1,000 endangered juvenile long-tail macaques to Cambodia for testing.
Acquisitions
In 1988, Charles River purchased Specific Pathogen Antigen Free Avian Services (SPAFAS) and serologic diagnostic services Merck, Sharp, and Dohme.
Between 1996 and 2000, the company acquired Endosafe, Inc. and Sierra Biomedical.
In October 2003, Charles River Laboratories merged with Inveresk, a research company based in the United Kingdom. The company was known then as Charles River Laboratories. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch.
In 2010, Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners, and Neuberger Berman. The proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal.
From 2008 to 2013, Charles River acquires several companies including NewLab Bioquality AG, MIR Preclinical Services, Piedmont Research Center, LLC, Cerebricon, Ltd., Accugenix, and Vital River, allowing the company to expand their research models and services portfolio to drug development and discovery markets in China.
The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish itself as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development.
In July 2015, the company announced it would acquire Celsis International for $212 million.
In 2016, the company announced it was set to acquire WIL Research for approximately $585 million in cash and Blue Stream Laboratories.
In August 2017, the business announced it would acquire Brains On-Line.
In January 2018, the company announced it would acquire KWS BioTest for up to £18 million ($24.4 million). In February of the same year, Charles River announced it would acquire MPI Research for approximately $800 million in cash. The transaction was completed on April 3, 2018.
In February 2019, the company announced it would acquire Citoxlab for €448 million in cash (approximately $500 million), including the former acquisitions of the French company, AccelLAB, Atlanbio and Solvo Biotechnology. The transaction was completed on April 29. In December of the same year the business announced it would acquire HemaCare for approximately $380 million in cash.
In August 2020, the company announced it would acquire Cellero for $38 million in cash.
In January 2021, the company announced it would acquire Distributed Bio, Inc., an antibody discovery business.
In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million.
In March 2021, Charles River announced the acquisition of Retrogenix for $48 million.
In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million.
In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M.
In April 2022, the company announced it would acquire Explora BioLabs.
In January 2023, the business announced it would acquire SAMDI Tech, Inc.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealthcare
endüstriLife Sciences Tools & Services
çalışanlar18.300
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$4.02B2016-12-31 → 2025-12-27
Hisse Başına Kâr$-2.912016-12-31 → 2025-12-27
Serbest Nakit Akışı$518M2016-12-31 → 2025-12-27
Net kar marjı-6.0%2016-12-31 → 2025-12-27
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | CRL | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | -60.55Y ort. ≈191.6 | ≈191.6 | · | · | |
| F/S (TTM) | 3.55Y ort. ≈3.2 | ≈3.2 | 4.9 | Düşük değerli | |
| F/D (MRQ) | 4.95Y ort. ≈4.1 | ≈4.1 | 3.6 | Adil değer | |
| EV / EBITDA | 32.85Y ort. ≈16.9 | ≈16.9 | 25.4 | Düşük değerli | |
| Fiyat / Serbest Nakit Akışı (TTM) | 37.45Y ort. ≈28.8 | ≈28.8 | · | · | |
| Fiyat / Nakit Akışı (TTM) | 23.85Y ort. ≈17.3 | ≈17.3 | 26.2 | Düşük değerli | |
| EV / Revenue (EV / Gelir) | 3.55Y ort. ≈3.1 | ≈3.1 | · | · | |
| EV / FCF | 27.15Y ort. ≈28.3 | ≈28.3 | · | · | |
| Fiyat / Maddi Defter Değeri (MRQ) | 5.4 | · | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | CRL | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | 2.3%5Y ort. ≈10.8% | ≈10.8% | 12.1% | Aynı seviyede | |
| FAVÖK Marjı (TTM) | 9.7%5Y ort. ≈19.2% | ≈19.2% | 14.8% | En üst düzey | |
| Pretax Margin (Vergi Öncesi Kar Marjı) | -2.5%5Y ort. ≈8.6% | ≈8.6% | 12.4% | Zayıf | |
| Net Kâr Marjı (TTM) | -6.0%5Y ort. ≈6.3% | ≈6.3% | 10.8% | Zayıf | |
| ROA (TTM) | -3.2%5Y ort. ≈3.4% | ≈3.4% | 2.0% | Zayıf | |
| ROE (TTM) | -7.7%5Y ort. ≈9.0% | ≈9.0% | 3.3% | Zayıf | |
| ROIC | 1.1%5Y ort. ≈10.7% | ≈10.7% | 3.0% | Zayıf |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | CRL | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Borç / Öz Sermaye (MRQ) | 0.05Y ort. ≈0.0 | ≈0.0 | 0.1 | Düşük borç | |
| Cari Oran (MRQ) | 1.35Y ort. ≈1.4 | ≈1.4 | 1.8 | Düşük likidite | |
| Quick Ratio (Cari Oran) | 0.85Y ort. ≈0.9 | ≈0.9 | 1.2 | Düşük likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | CRL | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | -0.85%5Y ort. ≈6.9% | ≈6.9% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 0.33%5Y ort. ≈5.7% | ≈5.7% | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | 6.6% | · | · | · | |
| EPS YoY (EPS YB) | -97.8%5Y ort. ≈-17.6% | ≈-17.6% | · | · | |
| Net Income YoY (Net Gelir Yıllık Bazda) | -95.3%5Y ort. ≈-16.5% | ≈-16.5% | · | · | |
| EPS CAGR 3Y (EPS Bileşik Yıllık Büyüme Oranı 3Y) | -70.3% | · | · | · | |
| Net Income CAGR 3Y (Net Gelir Bileşik Yıllık Büyüme Oranı 3Y) | -61.6% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | CRL | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.55Y ort. ≈0.5 | ≈0.5 | 0.5 | Aynı seviyede | |
| Receivables Turnover (Alacak Devir Hızı) | 5.65Y ort. ≈5.5 | ≈5.5 | 5.6 | Aynı seviyede | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$219.4K | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
8.9%
Sonraki Rapor
Kas 03, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 12, 2026 | $3.02 | $2.76 | 9.2% |
| 31 Mart 2026 | $2.06 | $1.96 | 5.0% | |
| 31 Aralık 2025 | $2.39 | $2.37 | 0.98% | |
| 30 Eylül 2025 | $2.43 | $2.36 | 2.9% | |
| 30 Haziran 2025 | $3.12 | $2.52 | 23.7% | |
| 31 Mart 2025 | $2.34 | $2.10 | 11.4% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Cost of Revenue | · | · | · | · | · | · | · | · | $290M | $277M | $264M | $266M | |
| SG&A Expense | $743M | $751M | $748M | $665M | $620M | $529M | $518M | $444M | $371M | $365M | $300M | $269M | |
| Operating Income | $25M | $227M | $617M | $651M | $590M | $433M | $351M | $331M | $288M | $238M | $206M | $178M | |
| Interest Expense | · | · | $137M | $59M | $74M | $86M | $61M | $64M | $30M | $28M | $15M | $12M | |
| Interest Income | $5M | $9M | $5M | $780.0K | $652.0K | $834.0K | $2M | $812.0K | $690.0K | $1M | $1M | $1M | |
| Other Non-op | $-23M | $-17M | $96M | $31M | $-36M | $100M | $12M | $13M | $38M | $12M | $3M | $11M | |
| Pretax Income | $-100M | $93M | $581M | $623M | $481M | $447M | $304M | $282M | $297M | $223M | $195M | $178M | |
| Income Tax | $43M | $68M | $101M | $130M | $82M | $82M | $50M | $54M | $171M | $67M | $43M | $48M | |
| Net Income | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| EPS (Basic) | $-2.91 | $0.20 | $9.27 | $9.57 | $7.77 | $7.35 | $5.17 | $4.72 | $2.60 | $3.29 | $3.21 | $2.72 | |
| EPS (Diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 | |
| Shares (Basic) | 49,564,000 | 51,380,000 | 51,227,000 | 50,812,000 | 50,293,000 | 49,550,000 | 48,730,000 | 47,947,000 | 47,481,000 | 47,014,000 | 46,496,000 | 46,627,000 | |
| Shares (Diluted) | 49,564,000 | 51,628,000 | 51,451,000 | 51,301,000 | 51,425,000 | 50,611,000 | 49,693,000 | 49,018,000 | 48,564,000 | 47,958,000 | 47,634,000 | 47,558,000 | |
| EBITDA | $428M | $589M | $931M | $955M | $855M | $668M | $549M | $493M | $419M | $364M | $301M | $274M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $214M | $195M | $277M | $234M | $241M | $228M | $238M | $195M | $164M | $118M | $118M | $160M | |
| Short-term Investments | · | · | · | · | $1M | $1M | $941.0K | $885.0K | $28M | $4M | $21M | · | |
| Receivables | $709M | $721M | $780M | $752M | $643M | $618M | $514M | $472M | $430M | $364M | $270M | $258M | |
| Inventory | $299M | $279M | $380M | $256M | $199M | $186M | $161M | $128M | $115M | $96M | $94M | $89M | |
| Prepaid Expense | $129M | $106M | $83M | $108M | $97M | $73M | $56M | $49M | $81M | $45M | $47M | $45M | |
| Other Current Assets | · | · | · | · | · | $0 | $300.0K | $300.0K | $0 | $45M | $47M | $73M | |
| Current Assets | $1.45B | $1.40B | $1.61B | $1.44B | $1.27B | $1.20B | $1.02B | $898M | $827M | $657M | $559M | $579M | |
| PP&E (Net) | $1.66B | $1.60B | $1.64B | $1.47B | $1.29B | $1.12B | $1.04B | $933M | $782M | $756M | $678M | $677M | |
| PP&E (Gross) | $3.19B | $3.06B | $2.98B | $2.63B | $2.39B | $2.21B | $2.02B | $1.81B | $1.58B | $1.46B | $1.32B | $1.33B | |
| Accum. Depreciation | $1.54B | $1.45B | $1.34B | $1.16B | $1.10B | $1.09B | $978M | $874M | $801M | $706M | $645M | $655M | |
| Goodwill | $2.76B | $2.85B | $3.10B | $2.85B | $2.71B | $1.81B | $1.54B | $1.25B | $805M | $788M | $439M | $321M | |
| Intangibles | $340M | $723M | $864M | $955M | $1.06B | $788M | $689M | $611M | $370M | $394M | $281M | $281M | |
| Other Non-current Assets | $293M | $278M | $309M | $148M | $152M | $353M | $213M | $144M | $124M | $88M | $72M | $73M | |
| Total Assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Accounts Payable | $149M | $140M | $169M | $206M | $198M | $122M | $111M | $66M | $78M | $68M | $37M | $34M | |
| Accrued Liabilities | $270M | $232M | $228M | $220M | $229M | $150M | $139M | $107M | $90M | $84M | $89M | $67M | |
| Current Liabilities | $1.12B | $994M | $1.06B | $1.09B | $1.03B | $840M | $710M | $558M | $464M | $430M | $312M | $295M | |
| Capital Leases | $434M | $484M | $419M | $390M | $253M | $156M | $116M | · | · | · | · | · | |
| Deferred Tax | $95M | $107M | $191M | $216M | $240M | $217M | $167M | $144M | $90M | $56M | $48M | $23M | |
| Other Non-current Liabilities | $138M | $195M | $223M | $175M | $243M | $205M | $183M | $179M | $195M | $159M | $89M | $100M | |
| Total Liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B | $3.03B | $2.52B | $1.87B | $1.86B | $1.30B | $1.17B | |
| Long-term Debt | · | · | · | · | · | · | · | $1.61B | $1.09B | $1.18B | $814M | $717M | |
| Total Debt | $166.0K | $155.0K | $3M | $1M | $101.0K | $47M | $36M | $1.65B | $1.12B | $1.21B | $836M | $754M | |
| Common Stock | $492.0K | $511.0K | $513.0K | $509.0K | $505.0K | $498.0K | $489.0K | $482.0K | $875.0K | $863.0K | $855.0K | $845.0K | |
| Retained Earnings | $1.39B | $1.81B | $1.89B | $1.43B | $981M | $625M | $280M | $42M | $289M | $165M | $11M | $-139M | |
| Treasury Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $55.0K | $1.66B | $1.55B | $1.54B | $1.42B | |
| AOCI | $-172M | $-317M | $-196M | $-262M | $-165M | $-139M | $-178M | $-173M | $-145M | $-254M | $-136M | $-74M | |
| Stockholders' Equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B | $2.11B | $1.63B | $1.32B | $1.05B | $837M | $733M | $672M | |
| Liabilities + Equity | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Shares Outstanding | 49,217,000 | 51,141,000 | 51,338,000 | 50,944,000 | 50,480,000 | 49,767,000 | 48,936,000 | 48,209,000 | 47,402,000 | 47,363,000 | 46,698,000 | 47,327,000 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $403M | $362M | $314M | $304M | $266M | $235M | $198M | $162M | $131M | $127M | $95M | $96M | |
| Stock-based Comp | $71M | $70M | $72M | $74M | $71M | $56M | $57M | $47M | $44M | $44M | $40M | $31M | |
| Deferred Tax | $-75M | $-67M | $-51M | $-33M | $-20M | $2M | $-21M | $-10M | $28M | $3M | $4M | $9M | |
| Amort. of Intangibles | $179M | $138M | $137M | $147M | $125M | $112M | $90M | $65M | $41M | $42M | $24M | $26M | |
| Restructuring | $100M | $107M | $30M | $8M | $7M | $13M | $14M | $10M | $5M | $18M | $8M | $8M | |
| Other Non-cash | $483M | $348M | $-126M | $-211M | $53M | $-111M | $-5M | $16M | $-8M | $-28M | $-395.0K | · | |
| Operating Cash Flow | $738M | $735M | $684M | $620M | $761M | $547M | $481M | $441M | $318M | $317M | $307M | $252M | |
| CapEx | $219M | $233M | $319M | $325M | $229M | $167M | $141M | $140M | $82M | $55M | $63M | $57M | |
| Investing Cash Flow | $-209M | $-245M | $-563M | $-608M | $-1.44B | $-602M | $-682M | $-955M | $-73M | $-693M | · | · | |
| Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | $237M | $1.04B | · | · | |
| Net Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | · | · | · | · | |
| Stock Repurchased | $361M | $119M | $24M | $39M | $41M | $24M | $18M | $14M | $107M | $12M | $117M | $122M | |
| Net Stock Activity | $-361M | $-119M | $-24M | $-39M | $-41M | $-24M | $-18M | $-14M | $-107M | $-12M | $-117M | $-122M | |
| Financing Cash Flow | $-537M | $-551M | $-86M | $-42M | $673M | $47M | $232M | $558M | $-208M | $381M | · | · | |
| Net Change in Cash | $10M | $-79M | $43M | $-5M | $13M | $-7M | $43M | $31M | $46M | $-69.0K | $-43M | $4M | |
| Taxes Paid | $120M | $126M | $90M | $76M | $75M | $60M | $54M | $68M | · | · | · | · | |
| Free Cash Flow | $518M | $502M | $365M | $295M | $532M | $380M | $340M | $301M | $236M | $245M | $225M | $195M | |
| Levered FCF | · | · | $252M | $248M | $471M | $309M | $290M | $250M | $223M | $226M | $213M | $186M |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% | 15.1% | 13.7% | |
| Net Margin | -3.6% | 0.55% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% | 10.9% | · | |
| Pretax Margin | -2.5% | 2.3% | 14.1% | 15.7% | 13.6% | 15.3% | 11.6% | 12.4% | 16.0% | 13.3% | 14.3% | 13.7% | |
| EBITDA Margin | 10.7% | 14.5% | 22.6% | 24.0% | 24.2% | 22.8% | 20.9% | 21.8% | 22.5% | 21.6% | 22.1% | 21.1% | |
| ROA | -2.0% | 0.28% | 6.0% | 6.7% | 6.2% | 7.1% | 5.9% | 6.7% | 4.4% | 6.5% | 7.6% | · | |
| ROE | -4.4% | 0.63% | 14.4% | 17.6% | 16.8% | 19.4% | 17.1% | 19.2% | 13.1% | 19.7% | 21.2% | · | |
| ROIC | 1.1% | 1.8% | 14.2% | 17.3% | 19.3% | 16.4% | 17.6% | 9.0% | 5.6% | 8.1% | 10.2% | 9.1% |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 | 1.4 | 1.4 | 1.6 | 1.8 | 1.5 | 1.8 | 2.0 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 | 1.0 | 1.1 | 1.2 | 1.3 | 1.1 | 1.2 | 1.4 | |
| Debt / Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 1.1 | 1.4 | 1.1 | 1.1 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 1.2 | 1.0 | 1.4 | 1.1 | 1.1 | |
| Interest Coverage | · | · | 4.5 | 11.0 | 8.0 | 5.0 | 5.8 | 5.2 | 9.7 | 8.6 | 13.7 | 14.9 |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | 2.7 | 2.9 | 2.9 | 3.0 | |
| Receivables Turnover | 5.6 | 5.4 | 5.4 | 5.7 | 5.6 | 5.2 | 5.3 | 5.0 | 4.7 | 5.3 | 5.2 | 5.4 |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $64.30 | $67.69 | $70.06 | $58.42 | $50.21 | $42.49 | $33.40 | $27.33 | $22.05 | $17.67 | $15.70 | $14.20 | |
| Revenue / Share | $81.01 | $78.45 | $80.26 | $77.50 | $68.84 | $57.77 | $52.75 | $46.23 | $38.25 | $35.06 | · | · | |
| Cash Flow / Share | $14.88 | $14.23 | $13.29 | $12.08 | $14.79 | $10.80 | $9.68 | $9.00 | $6.55 | $6.26 | · | · | |
| Cash / Share | $4.34 | $3.81 | $5.39 | $4.59 | $4.78 | $4.59 | $4.86 | $4.05 | $3.46 | $2.48 | $2.53 | $3.38 | |
| EPS (TTM) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.85% | -1.9% | 3.9% | 12.3% | 21.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 0.33% | 4.6% | 12.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | -97.8% | -2.7% | 24.7% | 5.6% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | -70.3% | 8.6% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | -95.3% | -2.4% | 24.4% | 7.3% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | -61.6% | 9.2% | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Net Income TTM | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| Market Cap | $10.02B | $9.52B | $12.14B | $11.10B | $18.64B | $12.53B | $7.43B | $5.39B | $5.19B | $3.61B | $3.74B | $3.04B | |
| Enterprise Value | $9.81B | $9.33B | $11.86B | $10.87B | $18.40B | $12.34B | $7.23B | $6.84B | $6.12B | $4.70B | $4.46B | $3.64B | |
| P/E | -70.0 | 930.8 | 25.6 | 23.0 | 48.6 | 35.0 | 30.0 | 24.2 | 43.1 | 23.6 | 25.6 | 24.2 | |
| P/S | 2.5 | 2.4 | 2.9 | 2.8 | 5.3 | 4.3 | 2.8 | 2.4 | 2.8 | 2.1 | 2.7 | 2.3 | |
| P/B | 3.2 | 2.8 | 3.4 | 3.7 | 7.4 | 5.9 | 4.5 | 4.1 | 5.0 | 4.3 | 5.1 | 4.5 | |
| P / Tangible Book | 166.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 13.6 | 13.0 | 17.7 | 17.9 | 24.5 | 22.9 | 15.5 | 12.2 | 16.3 | 12.0 | 13.0 | 12.1 | |
| P / FCF | 19.3 | 19.0 | 33.2 | 37.6 | 35.0 | 33.0 | 21.8 | 17.9 | 22.0 | 14.7 | 16.6 | 15.6 | |
| EV / EBITDA | 22.9 | 15.8 | 12.7 | 11.4 | 21.5 | 18.5 | 13.2 | 13.9 | 14.6 | 12.9 | 14.8 | 13.3 | |
| EV / FCF | 18.9 | 18.6 | 32.5 | 36.9 | 34.6 | 32.5 | 21.2 | 22.7 | 26.0 | 19.2 | 19.8 | 18.6 | |
| EV / Revenue | 2.4 | 2.3 | 2.9 | 2.7 | 5.2 | 4.2 | 2.8 | 3.0 | 3.3 | 2.8 | 3.3 | 2.8 | |
| Earnings Yield | -1.4% | 0.11% | 3.9% | 4.3% | 2.1% | 2.9% | 3.3% | 4.1% | 2.3% | 4.2% | 3.9% | 4.1% |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00B | $996M | $994M | $1.00B | $1.03B | $984M | $1.00B | $1.01B | $1.03B | $1.01B | $1.01B | $1.03B | $1.03B | $1.10B | $989M | |
| Cost of Revenue | · | · | · | · | · | · | · | $661M | $672M | $667M | · | $665M | $652M | · | · | |
| SG&A Expense | $229M | $159M | $196M | $178M | $192M | $178M | $196M | $199M | $170M | $186M | $197M | $176M | $175M | $200M | $184M | |
| Operating Income | $120M | $120M | $-283M | $134M | $100M | $75M | $-168M | $117M | $152M | $126M | $133M | $152M | $168M | $164M | $151M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $34M | $34M | · | $11M | |
| Interest Income | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $3M | $2M | $2M | $1M | $806.0K | $343.0K | $122.0K | |
| Other Non-op | $-37M | $-124M | $12M | $-23M | $154.0K | $-12M | $-23M | $3M | $-2M | $6M | $108M | $-6M | $-3M | $116M | $-17M | |
| Income Tax | $54M | $-15M | $-18M | $32M | $19M | $10M | $-3M | $21M | $25M | $25M | $20M | $25M | $27M | $56M | $25M | |
| Net Income | $-1M | $-15M | $-277M | $54M | $52M | $25M | $-214M | $70M | $94M | $73M | $187M | $87M | $103M | $187M | $96M | |
| EPS (Basic) | $-0.03 | $-0.30 | $-5.58 | $1.11 | $1.06 | $0.50 | $-4.20 | $1.34 | $1.75 | $1.31 | $3.65 | $1.70 | $2.02 | $3.68 | $1.90 | |
| EPS (Diluted) | $-0.03 | $-0.30 | $-5.57 | $1.10 | $1.06 | $0.50 | $-4.17 | $1.33 | $1.74 | $1.30 | $3.64 | $1.69 | $2.01 | $3.66 | $1.88 | |
| Shares (Basic) | 48,021,000 | 48,951,000 | · | 49,213,000 | 49,149,000 | 50,677,000 | · | 51,394,000 | 51,551,000 | 51,437,000 | · | 51,283,000 | 51,097,000 | · | 50,870,000 | |
| Shares (Diluted) | 48,021,000 | 48,951,000 | · | 49,426,000 | 49,316,000 | 50,853,000 | · | 51,583,000 | 51,846,000 | 51,842,000 | · | 51,607,000 | 51,428,000 | · | 51,283,000 | |
| EBITDA | $187M | $187M | · | $219M | $220M | $195M | · | $206M | $238M | $211M | · | $230M | $245M | · | $226M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $192M | $192M | $214M | $207M | $183M | $229M | $195M | $210M | $179M | $327M | · | $157M | $202M | · | $194M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $950.0K | |
| Receivables | $712M | $700M | $709M | $734M | $768M | $757M | $721M | $754M | $762M | $787M | · | $799M | $788M | · | $771M | |
| Inventory | $346M | $360M | $299M | $303M | $280M | $290M | $279M | $336M | $349M | $361M | · | $293M | $263M | · | $262M | |
| Prepaid Expense | $179M | $135M | $129M | $166M | $130M | $100M | $106M | $102M | $111M | $99M | · | $93M | $92M | · | $97M | |
| Current Assets | $1.53B | $1.49B | $1.45B | $1.53B | $1.47B | $1.51B | $1.40B | $1.49B | $1.50B | $1.67B | · | $1.44B | $1.45B | · | $1.42B | |
| PP&E (Net) | $1.49B | $1.51B | $1.66B | $1.59B | $1.61B | $1.59B | $1.60B | · | · | · | · | · | · | · | · | |
| PP&E (Gross) | $2.96B | $2.94B | $3.19B | $3.09B | $3.10B | $3.05B | $3.06B | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $1.46B | $1.43B | $1.54B | $1.50B | $1.50B | $1.46B | $1.45B | · | · | · | · | · | · | · | · | |
| Goodwill | $3.08B | $3.04B | $2.76B | $2.92B | $2.94B | $2.87B | $2.85B | $3.12B | $3.08B | $3.07B | · | $2.88B | $2.90B | · | $2.78B | |
| Intangibles | $253M | $249M | $340M | $571M | $602M | $656M | $723M | $778M | $800M | $828M | · | $886M | $958M | · | $968M | |
| Other Non-current Assets | $588M | $826M | $293M | $291M | $296M | $294M | $278M | $307M | $301M | $303M | · | $155M | $154M | · | $430M | |
| Total Assets | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Accounts Payable | $141M | $134M | $149M | $170M | $146M | $149M | $140M | $136M | $133M | $130M | · | $136M | $120M | · | $182M | |
| Accrued Liabilities | $380M | $372M | $270M | $229M | $232M | $242M | $232M | $208M | $192M | $191M | · | $198M | $221M | · | $197M | |
| Current Liabilities | $1.13B | $1.09B | $1.12B | $1.12B | $1.08B | $1.05B | $994M | $1.01B | $948M | $955M | · | $994M | $981M | · | $1.01B | |
| Capital Leases | $408M | $393M | $434M | $443M | $454M | $475M | $484M | $433M | $429M | $418M | · | $390M | $418M | · | $369M | |
| Deferred Tax | $79M | $81M | $95M | $123M | $109M | $107M | $107M | $168M | $165M | $180M | · | $185M | $212M | · | $196M | |
| Other Non-current Liabilities | $403M | $511M | $138M | $189M | $185M | $196M | $195M | $237M | $225M | $235M | · | $173M | $187M | · | $195M | |
| Total Liabilities | $4.64B | $4.74B | $3.92B | $4.06B | $4.16B | $4.34B | $4.02B | $4.18B | $4.18B | $4.45B | · | $4.26B | $4.54B | · | $4.71B | |
| Total Debt | $5M | $7M | · | $54.0K | $98.0K | $121.0K | · | $157.0K | $435.0K | $459.0K | · | $797.0K | · | · | $0 | |
| Common Stock | $496.0K | $493.0K | $492.0K | $514.0K | $513.0K | $512.0K | $511.0K | $517.0K | $517.0K | $515.0K | · | $514.0K | $512.0K | · | $510.0K | |
| Retained Earnings | $1.37B | $1.37B | $1.39B | $1.94B | $1.89B | $1.84B | $1.81B | $2.12B | $2.05B | $1.96B | · | $1.72B | $1.54B | · | $1.28B | |
| Treasury Stock | $323M | $210M | $0 | $363M | $363M | $357M | $0 | $120M | $18M | $9M | · | $24M | $19M | · | $38M | |
| AOCI | $-196M | $-191M | $-172M | $-192M | $-166M | $-265M | $-317M | $-193M | $-270M | $-250M | · | $-268M | $-239M | · | $-396M | |
| Stockholders' Equity | $2.84B | $2.94B | $3.16B | $3.41B | $3.35B | $3.19B | $3.46B | $3.78B | $3.72B | $3.64B | · | $3.31B | $3.11B | · | $2.63B | |
| Liabilities + Equity | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Shares Outstanding | 47,728,000 | 48,167,000 | 49,217,000 | 49,215,000 | 49,209,000 | 49,115,000 | 51,141,000 | 51,134,000 | 51,613,000 | 51,510,000 | · | 51,296,000 | 51,182,000 | 50,944,000 | 50,877,000 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $67M | $67M | $78M | $85M | $120M | $120M | $102M | $88M | $86M | $85M | $81M | $79M | $77M | $78M | $75M | |
| Stock-based Comp | $20M | $22M | $18M | $23M | $17M | $13M | $17M | $19M | $17M | $17M | $20M | $23M | $13M | $22M | $22M | |
| Amort. of Intangibles | $15M | $15M | $21M | $27M | $65M | $65M | $41M | $32M | $32M | $33M | $34M | $34M | $35M | $35M | $36M | |
| Restructuring | $23M | $32M | $26M | $17M | $32M | $24M | $41M | $31M | $18M | $17M | $8M | $15M | $3M | $4M | $1M | |
| Other Non-cash | · | $-34M | · | · | · | $13M | · | · | · | $-45M | · | · | $-84M | · | · | |
| Operating Cash Flow | $180M | $41M | $148M | $214M | $205M | $172M | $159M | $252M | $194M | $130M | $221M | $205M | $109M | $235M | $133M | |
| CapEx | $31M | $56M | $89M | $36M | $35M | $59M | $76M | $39M | $39M | $79M | $78M | $66M | $107M | $89M | $72M | |
| Investing Cash Flow | $28M | $-408M | $-93M | $-34M | $-37M | $-45M | $-76M | $-21M | $-62M | $-86M | $-238M | $-80M | $-169M | $44M | $-92M | |
| Debt Issued | $353M | $912M | $157M | $107M | $547M | $416M | $105M | $236M | $440M | $301M | $443M | $51M | $192M | $154M | $618M | |
| Net Debt Issued | · | $912M | · | · | · | $416M | · | · | · | $301M | · | · | $192M | · | · | |
| Stock Repurchased | $116M | $208M | $96.0K | $93.0K | $7M | $353M | $124.0K | $101M | $9M | $9M | $139.0K | $38.0K | $19M | $159.0K | $24.0K | |
| Net Stock Activity | · | $-208M | · | · | · | $-353M | · | · | · | $-9M | · | · | $-19M | · | · | |
| Financing Cash Flow | $-165M | $348M | $-52M | $-153M | $-227M | $-105M | $-76M | $-208M | $-286M | $18M | $124M | $-163M | $25M | $-249M | $-52M | |
| Net Change in Cash | $42M | $-18M | $7M | $24M | $-47M | $26M | $-6M | $31M | $-158M | $54M | $119M | $-43M | $-32M | $45M | $-11M | |
| Taxes Paid | $16M | $2M | $27M | $19M | $57M | $17M | $31M | $23M | $53M | $19M | $15M | $14M | $14M | · | · | |
| Free Cash Flow | · | $-15M | · | · | · | $112M | · | · | · | $51M | · | · | $3M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.9% | 12.0% | · | 13.3% | 9.7% | 7.6% | · | 11.6% | 14.8% | 12.4% | · | 14.8% | 16.3% | · | 15.3% | |
| Net Margin | -0.15% | -1.5% | · | 5.4% | 5.1% | 2.6% | · | 6.9% | 9.2% | 7.2% | · | 8.5% | 10.0% | · | 9.8% | |
| EBITDA Margin | 18.6% | 18.8% | · | 21.8% | 21.3% | 19.8% | · | 20.4% | 23.2% | 20.9% | · | 22.4% | 23.8% | · | 22.8% | |
| ROA | -0.02% | -0.19% | · | 0.70% | 0.67% | 0.32% | · | 0.89% | 1.2% | 0.92% | · | 1.2% | · | · | 1.3% | |
| ROE | -0.05% | -0.48% | · | 1.5% | 1.5% | 0.75% | · | 2.0% | 2.7% | 2.2% | · | 2.9% | · | · | 3.8% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | · | 1.4 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 1.5 | · | · | 1.4 | |
| Quick Ratio | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.9 | · | 1.0 | 1.0 | 1.2 | · | 1.0 | · | · | 1.0 | |
| Debt / Equity | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 3.6 | · | 4.5 | 4.9 | · | 13.3 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | · | 2.1 | 2.1 | 2.1 | · | · | · | · | · | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.4 | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | · | · | 1.4 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $59.50 | $61.05 | · | $69.20 | $68.14 | $65.04 | · | $73.97 | $72.13 | $70.67 | · | $64.45 | · | · | $51.63 | |
| Revenue / Share | $20.91 | $20.34 | · | $20.33 | $20.93 | $19.35 | · | $19.58 | $19.79 | $19.51 | · | $19.89 | $20.02 | · | $19.29 | |
| Cash Flow / Share | · | $0.84 | · | · | · | $3.38 | · | · | · | $2.51 | · | · | $2.13 | · | · | |
| Cash / Share | $4.02 | $3.98 | · | $4.21 | $3.72 | $4.67 | · | $4.11 | $3.47 | $6.35 | · | $3.06 | · | · | $3.81 | |
| EPS (TTM) | $-4.80 | $-3.71 | · | $-1.51 | $-1.28 | $-0.60 | · | $8.01 | $8.37 | $8.52 | · | $9.25 | $9.68 | · | $8.49 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.00B | $4.03B | · | $4.02B | $4.03B | $4.02B | · | $4.06B | $4.08B | $4.11B | · | $4.22B | $4.09B | · | $3.78B | |
| Net Income TTM | $-238M | $-185M | · | $-82M | $-67M | $-25M | · | $424M | $442M | $444M | · | $475M | $496M | · | $436M | |
| Market Cap | $10.30B | $7.67B | · | $7.31B | $7.38B | $7.64B | · | $10.14B | $10.66B | $13.96B | · | $10.05B | · | · | $9.54B | |
| Enterprise Value | $10.11B | $7.48B | · | $7.10B | $7.20B | $7.41B | · | $9.93B | $10.48B | $13.63B | · | $9.90B | · | · | $9.35B | |
| P/E | -44.9 | -42.9 | · | -98.4 | -117.2 | -259.2 | · | 24.8 | 24.7 | 31.8 | · | 21.2 | 20.8 | · | 22.1 | |
| P/S | 2.6 | 1.9 | · | 1.8 | 1.8 | 1.9 | · | 2.5 | 2.6 | 3.4 | · | 2.4 | 2.5 | · | 2.5 | |
| P/B | 3.6 | 2.6 | · | 2.1 | 2.2 | 2.4 | · | 2.7 | 2.9 | 3.8 | · | 3.0 | · | · | 3.6 | |
| P / Cash Flow | · | 186.6 | · | · | · | 44.5 | · | · | · | 107.5 | · | · | · | · | · | |
| EV / Revenue | 2.5 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.4 | 2.6 | 3.3 | · | 2.3 | 2.5 | · | 2.5 | |
| Earnings Yield | -2.2% | -2.3% | · | -1.0% | -0.85% | -0.39% | · | 4.0% | 4.0% | 3.1% | · | 4.7% | 4.8% | · | 4.5% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 |
|---|---|---|---|---|---|
| Gelir | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| Faaliyet Kâr Marjı % | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% |
| Net Gelir | $-144M | $22M | $475M | $486M | $391M |
| Seyreltilmiş Hisse Başı Kâr | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
| Metrik | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cari Oran | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 |
| Cari Oran | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 |
| Metrik | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $518M | $502M | $365M | $295M | $532M |
Kurumsal Sahipler (13F) 607 dosya · $13.6B toplam · Tarih itibarıyla 30 Eylül 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
607
Tutulan Değer
$13.6B
Yeni pozisyonlar
74
Çıkan pozisyonlar
62
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 74 (-17 önceki Ç'ye göre) | 62 (-19 önceki Ç'ye göre) | 193 (0 önceki Ç'ye göre) | 204 (+13 önceki Ç'ye göre) | +2.8M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| VANGUARD GROUP INC | $1.174.373.670 | 5.887.175 | 8,65% | Hisse senetleri |
| FMR LLC | $961.533.236 | 4.239.752 | 7,09% | Hisse senetleri |
| BlackRock, Inc. | $861.475.349 | 3.798.560 | 6,35% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $714.227.026 | 3.149.288 | 5,26% | Hisse senetleri |
| Invesco Ltd. | $676.919.391 | 2.984.785 | 4,99% | Hisse senetleri |
| HARRIS ASSOCIATES L P | $508.269.048 | 2.241.144 | 3,75% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $501.427.927 | 2.210.979 | 3,70% | Hisse senetleri |
| Allspring Global Investments Holdings, LLC | $436.473.035 | 1.905.247 | 3,22% | Hisse senetleri |
| STATE STREET CORP | $422.800.968 | 1.864.284 | 3,12% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $373.848.597 | 1.648.450 | 2,76% | Hisse senetleri |
| ARIEL INVESTMENTS, LLC | $341.587.697 | 1.506.185 | 2,52% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $295.598.099 | 1.305.738 | 2,18% | Hisse senetleri |
| WELLINGTON MANAGEMENT GROUP LLP | $292.210.525 | 1.288.463 | 2,15% | Hisse senetleri |
| CITADEL ADVISORS LLC | $270.696.771 | 1.193.601 | 1,99% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $265.930.779 | 1.172.586 | 1,96% | Hisse senetleri |
| EARNEST PARTNERS LLC | $254.007.295 | 1.120.011 | 1,87% | Hisse senetleri |
| AMERIPRISE FINANCIAL INC | $199.834.979 | 881.189 | 1,47% | Hisse senetleri |
| NEUBERGER BERMAN GROUP LLC | $195.633.630 | 862.704 | 1,44% | Hisse senetleri |
| SEI INVESTMENTS CO | $184.499.540 | 813.530 | 1,36% | Hisse senetleri |
| MORGAN STANLEY | $181.542.851 | 800.487 | 1,34% | Hisse senetleri |
| Clearbridge Investments, LLC | $177.185.527 | 781.276 | 1,31% | Hisse senetleri |
| COOKE & BIELER LP | $171.369.328 | 755.630 | 1,26% | Hisse senetleri |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $157.642.604 | 682.173 | 1,16% | Hisse senetleri |
| VICTORY CAPITAL MANAGEMENT INC | $150.762.735 | 664.768 | 1,11% | Hisse senetleri |
| UBS Group AG | $146.675.752 | 646.747 | 1,08% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $145.100.822 | 639.803 | 1,07% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $110.324.717 | 486.462 | 0,81% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $106.061.291 | 467.663 | 0,78% | Hisse senetleri |
| BANK OF MONTREAL /CAN/ | $104.270.783 | 459.768 | 0,77% | Hisse senetleri |
| NORTHERN TRUST CORP | $101.169.205 | 446.092 | 0,75% | Hisse senetleri |
| Gotham Asset Management, LLC | $98.233.181 | 433.146 | 0,72% | Hisse senetleri |
| Amundi | $93.528.650 | 412.402 | 0,69% | Hisse senetleri |
| NORGES BANK | $83.921.372 | 370.040 | 0,62% | Hisse senetleri |
| MARSHALL WACE, LLP | $77.787.835 | 342.995 | 0,57% | Hisse senetleri |
| Iron Triangle Partners LP | $75.748.141 | 379.728 | 0,56% | Hisse senetleri |
| CITIGROUP INC | $71.714.853 | 316.217 | 0,53% | Hisse senetleri |
| BNP PARIBAS FINANCIAL MARKETS | $69.108.583 | 304.725 | 0,51% | Hisse senetleri |
| Bank of New York Mellon Corp | $69.054.385 | 304.486 | 0,51% | Hisse senetleri |
| Boston Trust Walden Corp | $65.523.486 | 288.917 | 0,48% | Hisse senetleri |
| JPMORGAN CHASE & CO | $65.085.033 | 286.317 | 0,48% | Hisse senetleri |
| ALLIANCEBERNSTEIN L.P. | $64.615.913 | 374.585 | 0,48% | Hisse senetleri |
| SNYDER CAPITAL MANAGEMENT L P | $63.899.443 | 281.756 | 0,47% | Hisse senetleri |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $63.174.169 | 278.558 | 0,47% | Hisse senetleri |
| DEUTSCHE BANK AG\ | $62.723.084 | 276.569 | 0,46% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $61.384.115 | 270.665 | 0,45% | Hisse senetleri |
| PRIMECAP MANAGEMENT CO/CA/ | $60.523.448 | 266.870 | 0,45% | Hisse senetleri |
| RAYMOND JAMES FINANCIAL INC | $58.234.910 | 256.779 | 0,43% | Hisse senetleri |
| Meridiem Capital Partners LP | $56.012.367 | 246.979 | 0,41% | Hisse senetleri |
| Alyeska Investment Group, L.P. | $53.295.650 | 235.000 | 0,39% | Hisse senetleri |
| LOOMIS SAYLES & CO L P | $50.725.593 | 223.668 | 0,37% | Hisse senetleri |
Aktivistler ve %5+ sahipler 6 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| JANA PARTNERS LLC ×4 başvurular | 04 Ağustos 2011 | · | İlk başvuru | · | SEC |
| Relational Investors, LLC, Relational Investors Mid-Cap Fund I, L.P., Relational Investors Mid-Cap Fund II, L.P., Ralph V. Whitworth, David H. Batchelder, California State Teachers’ Retirement System ×3 başvurular | 09 Şubat 2011 | · | İlk başvuru | · | SEC |
| Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger Berman Management ×3 başvurular | 07 Aralık 2010 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 16 Haziran 2010 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 07 Haziran 2010 | · | İlk başvuru | Pasif yatırım | SEC |
| Charles River Laboratories International, Inc. IRS No. 061397316 | 05 Mayıs 2010 | · | İlk başvuru | Yönetim kurulu kampanyası | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 57 içeriden öğrenenler · 23 yöneticiler · 29 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Birgit Girshick | Chief Executive Officer | 19 Ağustos 2026 G | 35.485 | 0 | 1 | $-1.819.350 |
| Glenn Coleman | EVP & Chief Financial Officer | 30 Eylül 2026 P | 27.762 | 1 | 0 | $2.974 |
| Flavia Pease | Corporate Executive VP & CFO | 31 Mayıs 2025 F | 17.297 | 0 | 0 | $0 |
| David Ross Smith | Corporate Executive VP & CFO | 03 Mart 2022 M | 25.819 | 0 | 0 | $0 |
| Davide Molho | President & COO | 24 Temmuz 2018 M | 17.155 | 0 | 0 | $0 |
| Shannon M Parisotto | CEVP, Disc & Safety Assessment | 19 Ağustos 2026 M | 4.807 | 0 | 3 | $-2.965.466 |
| Mark Mintz | EVP, Chief Information Officer | 31 Mayıs 2026 F | 9.546 | 0 | 0 | $0 |
| William D Barbo | Corporate Executive VP & CCO | 07 Kasım 2024 G | 23.337 | 0 | 0 | $0 |
| John W Kuo | CEVP General Counsel & CCO | 01 Haziran 2020 A | 3.171 | 0 | 0 | $0 |
| David P Johst | Corporate Executive VP | 29 Mayıs 2020 A | 224.478 | 0 | 0 | $0 |
| John J Crowley | SVP, Chief Accounting Officer | 01 Ekim 2016 F | 5.599 | 0 | 0 | $0 |
| Nancy Gillett | Corporate Executive VP | 02 Mart 2016 S | 11.034 | 0 | 0 | $0 |
| Jorg Geller | Corporate Executive VP | 25 Şubat 2015 M | 14.094 | 0 | 0 | $0 |
| RENAUD REAL H | Corp. Executive VP | 11 Ağustos 2010 F | 74.390 | 0 | 0 | $0 |
| Christopher Berthoux | Executive Vice President | 26 Şubat 2010 A | 31.897 | 0 | 0 | $0 |
| Joanne P Acford | Corp. Sr VP, GC and Corp. Sec | 11 Ağustos 2007 F | 37.109 | 0 | 0 | $0 |
| David J Elliott | Officer | 29 Haziran 2007 M | 11.750 | 0 | 0 | $0 |
| Cheri L Walker | Corporate Senior VP | 01 Mayıs 2007 A | 6.262 | 0 | 0 | $0 |
| Stephanie B Wells | Senior Vice President | 02 Nisan 2007 A | 11.500 | 0 | 0 | $0 |
| Nicholas Ventresca | Senior Vice President | 02 Nisan 2007 F | 12.713 | 0 | 0 | $0 |
| John C Ho | Senior Vice President | 23 Şubat 2007 A | 12.710 | 0 | 0 | $0 |
| Brian Bathgate | Corporate Vice President | 27 Şubat 2006 S | 16.134 | 0 | 0 | $0 |
| Alastair Stuart Mcewan | Corporate VP | 23 Aralık 2004 M | 8.000 | 0 | 0 | $0 |
| James C Foster | Yönetim kurulu üyesi | 25 Ağustos 2026 M | 31.596 | 0 | 3 | $-34.844.875 |
| Nancy C Andrews | Yönetim kurulu üyesi | 18 Ağustos 2026 M | 1.438 | 0 | 1 | $-163.443 |
| Steven Barg | Yönetim kurulu üyesi | 02 Haziran 2026 A | 3.287 | 0 | 0 | $0 |
| Reshema Kemps-Polanco | Yönetim kurulu üyesi | 08 Mayıs 2026 A | 4.563 | 0 | 0 | $0 |
| George Llado | Yönetim kurulu üyesi | 08 Mayıs 2026 A | 6.702 | 0 | 0 | $0 |
| Abraham Ceesay | Yönetim kurulu üyesi | 08 Mayıs 2026 A | 2.384 | 0 | 0 | $0 |
| Mark J Enyedy | Yönetim kurulu üyesi | 08 Mayıs 2026 A | 2.384 | 0 | 0 | $0 |
| Paul W Graves | Yönetim kurulu üyesi | 08 Mayıs 2026 A | 2.384 | 0 | 0 | $0 |
| Craig B. Thompson | Yönetim kurulu üyesi | 08 Mayıs 2026 A | 3.851 | 0 | 0 | $0 |
| Martin Mackay | Yönetim kurulu üyesi | 08 Mayıs 2026 A | 17.137 | 0 | 0 | $0 |
| Virginia M Wilson | Yönetim kurulu üyesi | 08 Mayıs 2026 A | 6.349 | 0 | 0 | $0 |
| George Massaro | Yönetim kurulu üyesi | 15 Mayıs 2025 S | 5.575 | 0 | 0 | $0 |
| Richard F Wallman | Yönetim kurulu üyesi | 07 Kasım 2024 S | 0 | 0 | 0 | $0 |
| Deborah Turner Kochevar | Yönetim kurulu üyesi | 13 Mayıs 2024 A | 7.894 | 0 | 0 | $0 |
| Robert J Bertolini | Yönetim kurulu üyesi | 13 Mayıs 2024 A | 32.802 | 0 | 0 | $0 |
| Richard C Reese | Yönetim kurulu üyesi | 15 Mayıs 2023 A | 65.541 | 0 | 0 | $0 |
| George M Milne JR | Yönetim kurulu üyesi | 07 Mayıs 2021 A | 29.079 | 0 | 0 | $0 |
| Stephen D Chubb | Yönetim kurulu üyesi | 23 Şubat 2021 M | 40.529 | 0 | 0 | $0 |
| Jean-Paul Mangeolle | Yönetim kurulu üyesi | 22 Mayıs 2019 A | 3.886 | 0 | 0 | $0 |
| William Waltrip | Yönetim kurulu üyesi | 05 Aralık 2012 S | 21.830 | 0 | 0 | $0 |
| Samuel O Thier MD | Yönetim kurulu üyesi | 09 Mayıs 2012 A | 18.230 | 0 | 0 | $0 |
| Douglas E Rogers | Yönetim kurulu üyesi | 07 Mayıs 2010 A | 12.859 | 0 | 0 | $0 |
| Nancy T Chang | Yönetim kurulu üyesi | 07 Mayıs 2010 A | 31.010 | 0 | 0 | $0 |
| Linda Mcgoldrick | Yönetim kurulu üyesi | 13 Şubat 2006 A | · | 0 | 0 | $0 |
| Walter S Nimmo | Yönetim kurulu üyesi | 25 Şubat 2005 S | 149.447 | 0 | 0 | $0 |
| John Urquhart | Yönetim kurulu üyesi | 17 Şubat 2005 A | 11.738 | 0 | 0 | $0 |
| Louise S Mccrary | Yönetim kurulu üyesi | 17 Şubat 2005 A | · | 0 | 0 | $0 |
| Robert Cawthorn | Yönetim kurulu üyesi | 02 Haziran 2004 G | 278.600 | 0 | 0 | $0 |
| Joseph W Laplume | · | 10 Ağustos 2026 G | 31.041 | 1 | 1 | $-61.124 |
| Victoria L Creamer | · | 06 Ağustos 2026 M | 30.051 | 0 | 1 | $-1.083.030 |
| Michael Gunnar Knell | · | 06 Ağustos 2026 M | 11.852 | 0 | 9 | $-1.730.250 |
| Thomas F Ackerman | · | 29 Şubat 2016 F | 111.346 | 0 | 0 | $0 |
| Dennis R Shaughnessy | · | 29 Kasım 2004 G | 35.511 | 0 | 0 | $0 |
| Michael F Ankcorn | · | 04 Kasım 2004 S | 0 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 108 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| EPSB · Harbor ETF Trust | 2,15% | 443 NS | 31 Temmuz 2026 | N-PORT |
| PTH · Invesco Exchange-Traded Fund Trust | 2,00% | 20.123 SH | 02 Ekim 2026 | Günlük |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,71% | 5.092 NS | 31 Temmuz 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,70% | 51.688 SH | 02 Ekim 2026 | Günlük |
| EPSV · Harbor ETF Trust | 1,59% | 415 NS | 31 Temmuz 2026 | N-PORT |
| EPMV · Harbor ETF Trust | 1,44% | 291 NS | 31 Temmuz 2026 | N-PORT |
| ALTL · Pacer Funds Trust | 1,09% | 4.303 NS | 31 Temmuz 2026 | N-PORT |
| IBB · iShares Trust | 0,96% | 363.741 SH | 11 Eylül 2026 | Günlük |
| LSEQ · Harbor ETF Trust | 0,93% | 614 NS | 31 Temmuz 2026 | N-PORT |
| HIBL · Direxion Shares ETF Trust | 0,74% | 2.375 NS | 31 Temmuz 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,66% | 259 NS | 31 Temmuz 2026 | N-PORT |
| SPHB · Invesco Exchange-Traded Fund Trust … | 0,66% | 22.191 SH | 02 Ekim 2026 | Günlük |
| PDP · Invesco Exchange-Traded Fund Trust | 0,66% | 33.984 SH | 02 Ekim 2026 | Günlük |
| PALC · Pacer Funds Trust | 0,61% | 5.509 NS | 31 Temmuz 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,49% | 12.141 NS | 31 Temmuz 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,45% | 6.439 NS | 31 Temmuz 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0,42% | 24.876 SH | 02 Ekim 2026 | Günlük |
| FFSM · FIDELITY COVINGTON TRUST | 0,40% | 25.814 NS | 31 Temmuz 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,34% | 209.615 NS | 31 Temmuz 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,28% | 7.783 NS | 31 Temmuz 2026 | N-PORT |
| ESML · iShares Trust | 0,24% | 25.082 SH | 11 Eylül 2026 | Günlük |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,24% | 20.898 NS | 31 Temmuz 2026 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0,24% | 25.378 NS | 31 Temmuz 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,23% | 13.626 NS | 31 Temmuz 2026 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0,23% | 701.498 SH | 19 Ağustos 2026 | Günlük |
| DFAS · Dimensional ETF Trust | 0,22% | 147.648 NS | 31 Temmuz 2026 | N-PORT |
| IYH · iShares Trust | 0,22% | 28.670 SH | 11 Eylül 2026 | Günlük |
| RSP · Invesco Exchange-Traded Fund Trust | 0,21% | 701.283 SH | 02 Ekim 2026 | Günlük |
| SMMD · iShares Trust | 0,19% | 26.152 SH | 11 Eylül 2026 | Günlük |
| IXJ · iShares Trust | 0,17% | 25.598 SH | 11 Eylül 2026 | Günlük |
| FHLC · FIDELITY COVINGTON TRUST | 0,17% | 23.486 NS | 31 Temmuz 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,16% | 148.331 SH | 19 Ağustos 2026 | Günlük |
| REVS · Columbia ETF Trust I | 0,15% | 2.111 NS | 31 Temmuz 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,15% | 3.646 NS | 31 Temmuz 2026 | N-PORT |
| WSML · iShares Trust | 0,14% | 6.080 SH | 11 Eylül 2026 | Günlük |
| IWS · iShares Trust | 0,13% | 73.404 SH | 11 Eylül 2026 | Günlük |
| VB · VANGUARD INDEX FUNDS | 0,13% | 1.102.914 SH | 19 Ağustos 2026 | Günlük |
| CURE · Direxion Shares ETF Trust | 0,13% | 947 NS | 31 Temmuz 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,12% | 42.976 NS | 31 Temmuz 2026 | N-PORT |
| IEUS · iShares Trust | 0,10% | 5.579 SH | 11 Eylül 2026 | Günlük |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,10% | 2.769 SH | 02 Ekim 2026 | Günlük |
| IWR · iShares Trust | 0,10% | 200.615 SH | 11 Eylül 2026 | Günlük |
| RECS · Columbia ETF Trust I | 0,10% | 23.999 NS | 31 Temmuz 2026 | N-PORT |
| XOEF · iShares Trust | 0,07% | 61 SH | 11 Eylül 2026 | Günlük |
| DFUV · Dimensional ETF Trust | 0,06% | 41.352 NS | 31 Temmuz 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,06% | 1.302 NS | 31 Temmuz 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,05% | 106.991 NS | 31 Temmuz 2026 | N-PORT |
| IVE · iShares Trust | 0,04% | 79.930 SH | 11 Eylül 2026 | Günlük |
| IUSV · iShares Trust | 0,04% | 42.675 SH | 11 Eylül 2026 | Günlük |
| SCZ · iShares Trust | 0,04% | 171.786 SH | 11 Eylül 2026 | Günlük |
| VSS · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,04% | 174.824 SH | 19 Ağustos 2026 | Günlük |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,04% | 11.139 SH | 19 Ağustos 2026 | Günlük |
| DCOR · Dimensional ETF Trust | 0,04% | 5.545 NS | 31 Temmuz 2026 | N-PORT |
| IWD · iShares Trust | 0,04% | 108.791 SH | 11 Eylül 2026 | Günlük |
| CHRI · Global X Funds | 0,03% | 11 NS | 31 Temmuz 2026 | N-PORT |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,03% | 29.579 SH | 19 Ağustos 2026 | Günlük |
| TOPC · iShares Trust | 0,03% | 32 SH | 11 Eylül 2026 | Günlük |
| PRF · Invesco Exchange-Traded Fund Trust | 0,03% | 9.073 SH | 02 Ekim 2026 | Günlük |
| DFSU · Dimensional ETF Trust | 0,02% | 2.431 NS | 31 Temmuz 2026 | N-PORT |
| XVV · iShares Trust | 0,02% | 576 SH | 11 Eylül 2026 | Günlük |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,02% | 1.258 SH | 02 Ekim 2026 | Günlük |
| PBP · Invesco Exchange-Traded Fund Trust | 0,02% | 287 SH | 02 Ekim 2026 | Günlük |
| EGLE · Global X Funds | 0,02% | 2 NS | 31 Temmuz 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,02% | 7.022 SH | 02 Ekim 2026 | Günlük |
| IVV · iShares Trust | 0,02% | 607.129 SH | 11 Eylül 2026 | Günlük |
| VOO · VANGUARD INDEX FUNDS | 0,02% | 1.250.774 SH | 19 Ağustos 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,02% | 1.530.468 SH | 19 Ağustos 2026 | Günlük |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,02% | 8.168 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,02% | 4.112 SH | 19 Ağustos 2026 | Günlük |
| ESGV · VANGUARD WORLD FUND | 0,02% | 11.106 SH | 19 Ağustos 2026 | Günlük |
| IWV · iShares Trust | 0,02% | 14.165 SH | 11 Eylül 2026 | Günlük |
| IWB · iShares Trust | 0,02% | 33.863 SH | 11 Eylül 2026 | Günlük |
| XRMI · Global X Funds | 0,02% | 41 NS | 31 Temmuz 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,02% | 9.979 NS | 31 Temmuz 2026 | N-PORT |
| XYLD · Global X Funds | 0,02% | 2.566 NS | 31 Temmuz 2026 | N-PORT |
| IYY · iShares Trust | 0,02% | 2.018 SH | 11 Eylül 2026 | Günlük |
| ITOT · iShares Trust | 0,02% | 63.582 SH | 11 Eylül 2026 | Günlük |
| PTLC · Pacer Funds Trust | 0,02% | 2.492 NS | 31 Temmuz 2026 | N-PORT |
| PHDG · Invesco Actively Managed Exchange-T… | 0,02% | 38 SH | 02 Ekim 2026 | Günlük |
| TILT · FlexShares Trust | 0,02% | 1.620 NS | 31 Temmuz 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,02% | 14.645 NS | 31 Temmuz 2026 | N-PORT |
| XYLG · Global X Funds | 0,02% | 45 NS | 31 Temmuz 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0,02% | 182 NS | 31 Temmuz 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0,02% | 1.141 NS | 31 Temmuz 2026 | N-PORT |
| XTR · Global X Funds | 0,01% | 3 NS | 31 Temmuz 2026 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0,01% | 332 NS | 31 Temmuz 2026 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0,01% | 3.766 NS | 31 Temmuz 2026 | N-PORT |
| IEUR · iShares Trust | 0,01% | 37.473 SH | 11 Eylül 2026 | Günlük |
| XCLR · Global X Funds | 0,01% | 2 NS | 31 Temmuz 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,01% | 1.973 SH | 02 Ekim 2026 | Günlük |
| VGK · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 110.946 SH | 19 Ağustos 2026 | Günlük |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 77.796 SH | 19 Ağustos 2026 | Günlük |
| VEA · VANGUARD TAX-MANAGED FUNDS | 0,01% | 447.656 SH | 19 Ağustos 2026 | Günlük |
| IDEV · iShares Trust | 0,01% | 52.174 SH | 11 Eylül 2026 | Günlük |
| IEFA · iShares Trust | 0,00% | 272.340 SH | 11 Eylül 2026 | Günlük |
| NEAR · iShares U.S. ETF Trust | 0,00% | 140.000 SH | 09 Eylül 2026 | Günlük |
| DFLV · Dimensional ETF Trust | 0,00% | 377 NS | 31 Temmuz 2026 | N-PORT |
| IXUS · iShares Trust | 0,00% | 22.623 SH | 11 Eylül 2026 | Günlük |
| VXUS · VANGUARD STAR FUNDS | 0,00% | 664.961 SH | 19 Ağustos 2026 | Günlük |
| VSGX · VANGUARD WORLD FUND | 0,00% | 8.805 SH | 19 Ağustos 2026 | Günlük |
| VGHY · VANGUARD FIXED INCOME SECURITIES FU… | · | · | 15 Temmuz 2026 | Günlük |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 15 Temmuz 2026 | Günlük |
| VPLS · VANGUARD MALVERN FUNDS | · | · | 15 Temmuz 2026 | Günlük |
| VSDB · VANGUARD MALVERN FUNDS | · | · | 15 Temmuz 2026 | Günlük |
| VGMS · VANGUARD MALVERN FUNDS | · | · | 15 Temmuz 2026 | Günlük |
| ISCB · iShares Trust | · | 2.146 SH | 11 Eylül 2026 | Günlük |
| ISCV · iShares Trust | · | 10.576 SH | 11 Eylül 2026 | Günlük |
| SMLF · iShares Trust | · | 18.703 SH | 11 Eylül 2026 | Günlük |
CRL Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 23 analist
AL
Medyan hedef
$322.00
+11,0%
6 26,1%
Güçlü Al
11 47,8%
Al
6 26,1%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
15 analist · 2026-10-02Ortalama hedef $305.00 +5,1%
Şimdi
Mevcut fiyat $290.19
Düşük$145.00
Ortalama$305.00
Yüksek$357.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | · |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | · |
| RVTY | $10.86B | 46.7 | 3.7% | 8.5% | 3.3% | · |
| TEM | · | -41.9 | 83.4% | -19.3% | -61.2% | · |
| TEM | · | -41.9 | 83.4% | -19.3% | -61.2% | · |
| TXG | $2.08B | -46.6 | 5.2% | -6.8% | -5.5% | 69.0% |
| TECH | $11.03B | 60.9 | -0.38% | 15.0% | 9.0% | 65.8% |
| RGEN | $9.23B | 190.5 | 16.4% | 6.6% | 2.4% | · |
| AVTR | $7.82B | -14.7 | -3.4% | -8.1% | -8.9% | 32.6% |
| BIO | · | · | · | · | · | · |
Son Haberler Bu şirketten bahseden son manşetler
Bio-Techne, Charles River Laboratories International'ı Geride Bırakarak 477. Sıraya Yerleşti
Nasdaq · 3 ay önce
Charles River Laboratories International Q1 Kazanç Araması Çağrısı Özetleri
Yahoo Finance · 4 ay, 3 hafta önce
Tokenleştirilmiş Kripto ABD Hazine Tahvilleri 14 Milyar Doların Yakınında, Circle ve BlackRock Büyümeyi Liderliyor
Yahoo Finance · 5 ay, 2 hafta önce
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 5, 2026